CytoDyn (OTCMKTS:CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies. The company has also initiated trials exploring leronlimab’s potential to modulate immune response in critically ill COVID-19 patients, capitalizing on the antibody’s mechanism of action to reduce inflammatory damage. CytoDyn’s research programs extend to combination therapies as well as collaborations with academic institutions and research centers.
Headquartered in Vancouver, Washington, CytoDyn maintains its research and development operations in the United States while engaging contract research organizations and clinical sites in North America, Europe, and other regions. The company works to build strategic partnerships to support global clinical development and regulatory submissions. CytoDyn holds certain licensing agreements for leronlimab and continues to explore additional collaborations to expand the antibody’s commercial reach.
Leadership at CytoDyn includes Nader Pourhassan, who serves as President and Chief Executive Officer, guiding the company through its clinical milestones and regulatory interactions. Since its founding, CytoDyn has emphasized a science-driven approach to address unmet medical needs in infectious diseases and oncology. The company remains committed to advancing its pipeline toward potential approvals and eventual commercialization.
